

S/N Unknown

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Anthony D. Sandler	Examiner:	Bradley L. Sisson
Serial No.:	Unknown	Group Art Unit:	Unknown
Filed:	Herewith	Docket:	875.099US1
Title:	METHOD FOR PREDICTING TUMOR RECURRENCE (Continuation-in-Part of U.S. Serial No. 09/705,146 filed November 2, 2000)		

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement.

The documents listed on the attached Form 1449 were previously cited by or submitted to the U.S. Patent Office in connection with Applicant's prior U.S. application, Serial No. 09/705146, filed on November 02, 2000, which is relied upon for an earlier filing date under 35 U.S.C. §120. Copies of the 19 cited articles are enclosed herewith.

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

ANTHONY D. SANDLER

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6961

Date 22 September 2003 By Ann S. Viksnins  
Ann S. Viksnins  
Reg. No. 37,748

"Express Mail" mailing label number: EV 332 580 335 US

Date of Deposit: September 22, 2003

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to the Commissioner for Patents, Mail Stop Patent Application, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)	Complete if Known	
	Application Number	Unknown
	Filing Date	Even Date Herewith
	First Named Inventor	Sandler, Anthony
	Group Art Unit	Unknown
	Examiner Name	Sisson, Bradley
Sheet 1 of 2		Attorney Docket No: 875.099US1

US PATENT DOCUMENTS						
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-6,001,962	12/14/1999	Ramer, J. K., et al.	580	324	11/15/1996
	US-6,077,709	06/20/2000	Bennett, C. F., et al.	435	375	09/29/1998
	US-6,103,237	08/15/2000	Saedi, M. S., et al.	424	185.1	03/26/1996

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
		ADIDA, C. , et al., "Anti-apoptosis gene, survivin, and prognosis of neuroblastoma", <u>The Lancet</u> , 351, (1998),pp. 882-883				
		AMBROSINI, G. , et al., "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma", <u>Nature Medicine</u> , 3 (8), (1997),pp. 917-921				
		ASHKENAZI, A. , et al., "Death Receptors: Signaling and Modulation", <u>Science</u> , 281 (5381), (1998),pp. 1305-1308				
		BRESLOW, N. , et al., "Epidemiology of Wilms Tumor", <u>Medical and Pediatric Oncology</u> , 21 (3), (1993),pp. 172-181				
		BRODEUR, G. M., et al., "Neuroblastoma", In: <u>Principles and Practice of Pediatric Oncology</u> , Chapter 29, (1997),pp. 761-797				
		DEVERAUX, QUINN L., et al., "X-Linked IAP is a Direct Inhibitor of Cell-Death Proteases", <u>Nature</u> , 388 (6639), (1997),pp. 300-304				
		DONALDSON, S. A., et al., "Expression of Fas/APO-1 by different clinical stages of human neuroblastoma", <u>Proceedings of the American Association for Cancer Research</u> , 40, Abstract No. 1141,(March 1999),p. 171				
		LI, F. , et al., "Control of apoptosis and mitotic spindle checkpoint by survivin", <u>Nature</u> , 396, (1998),pp. 580-584				
		LI, F. , et al., "Pleiotropic cell-division defects and apoptosis induced by interference with survivin function", <u>Nature Cell Biology</u> , 1 (8), (1999),pp. 461-466				
		LISTON, P. , et al., "Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes", <u>Nature</u> , 379, (1996),pp. 349-353				
		LOWRY, O. H., et al., "Protein Measurement With The Folin Phenol Reagent", <u>The Journal of Biological Chemistry</u> , 193, (1951),pp. 265-275				
		LU, C. , et al., "Expression of A Novel Antiapoptosis Gene, Survivin, Correlated with Tumor Cell Apoptosis and p53 Accumulation in Gastric Carcinomas", <u>Cancer Research</u> , 58 (9), (1998),pp. 1808-1812				
		MILLER, L. J., et al., "Apoptosis", <u>Science</u> , 281 (5381), (1998),p. 1301				
		SANDLER, A. , et al., "Survivin in Apoptosis and Solid Tumors of Childhood",				

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)	<b>Complete if Known</b>	
	<b>Application Number</b>	Unknown
	<b>Filing Date</b>	Even Date Herewith
	<b>First Named Inventor</b>	Sandler, Anthony
	<b>Group Art Unit</b>	Unknown
	<b>Examiner Name</b>	Sisson, Bradley
Sheet 2 of 2	Attorney Docket No: 875.099US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Surgical Forum, 85th Annual Clinical Congress, Volume L, (1999), pp. 571-572	
		SARELA, et al., "Expression of the Antiapoptosis Gene, Survivin, Predicts Death from Recurrent Colorectal Carcinoma", <u>Gut</u> , 46, (May, 2000), 645-650	
		SWANA, H. S., et al., "Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer", <u>The New England Journal of Medicine</u> , 341 (6), (1999), pp. 452-453	
		TAKAMIZAWA, S., et al., "Differential Apoptosis Gene Expression in Pediatric Tumors of the Kidney", <u>Journal of Pediatric Surgery</u> , 35 (2), (Feb. 2000), pp. 390-395	
		TAMM, I., et al., "IAP-Family Protein Survivin Inhibits Caspase Activity and Apoptosis Induced by Fas (CD95), Bax, Caspases, and Anticancer Drugs", <u>Cancer Research</u> , 58 (23), (1998), pp. 5315-5320	
		THOMPSON, C. B., "Apoptosis in the Pathogenesis and Treatment of Disease", <u>Science</u> , 267, (1995), pp. 1456-1462	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached